/

Empresas

En

No verificado

Enterome

Sobre qué escribimos

Anuncios brevesBiotecnologíaEventosFarmacéuticaMedicina Salud Bienestar

14 Comunicados de prensa

Ver todos los comunicados de prensa

20/07/2026

Biotecnología

Medicina Salud Bienestar

Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting

Fuente

Editor

1.00

0

14/06/2026

Biotecnología

Medicina Salud Bienestar

Enterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics™-induced CD8 T cell responses and clinical activity

Fuente

Editor

1.00

0

27/05/2026

Biotecnología

Medicina Salud Bienestar

Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma

Fuente

Editor

1.00

0

11/05/2026

Biotecnología

Medicina Salud Bienestar

Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes

Fuente

Editor

1.00

0

28/01/2026

Biotecnología

Medicina Salud Bienestar

Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors

Fuente

Editor

1.00

0

08/12/2025

Biotecnología

Medicina Salud Bienestar

Enterome presents strengthened interim Phase 2 results for lead OncoMimics™ immunotherapy EO2463 to treat follicular lymphoma at ASH

Fuente

Editor

1.00

0

01/12/2025

Biotecnología

Medicina Salud Bienestar

Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial

Fuente

Editor

1.00

0

12/11/2025

Biotecnología

Medicina Salud Bienestar

Enterome to present positive interim Phase 2 data for lead OncoMimics™ immunotherapy EO2463 in follicular lymphoma at American Society for Hematology (ASH) meeting

Fuente

Editor

1.00

0

15/10/2025

Biotecnología

Medicina Salud Bienestar

Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463

Fuente

Editor

1.00

0

22/06/2025

Biotecnología

Anuncios breves

Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0